Tag: RNA
Ipsen and Skyhawk Therapeutics announce the signing of a research collaboration agreement aimed at targeting RNA in rare neurological diseases – 04/22/2024 at 07:00
Ipsen Enters into Option Agreement for Exclusive Worldwide Rights for Successful Candidates in Collaboration Once the development candidate has been validated, Ipsen will be responsible for its continued development and…
Ipsen and Skyhawk Therapeutics agree on RNA targeting in rare neurological diseases – 04/22/2024 at 07:09
Ipsen SA IPN.PA: * IPSEN AND SKYHAWK THERAPEUTICS ANNOUNCE THE SIGNATURE OF A RESEARCH COLLABORATION AGREEMENT AIMING AT RNA TARGETING IN RARE NEUROLOGICAL DISEASES * IPSEN ENTERS INTO AN OPTION…
Almirall: Alliance with the Belgian etherna in messenger RNA
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
OSE Immunotherapeutics announces new public aid to support its innovation and research programs in the field of RNA Therapeutics – 08/01/2023 at 07:30
Nantes, France – August 1, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Company has received innovation aid of 200,000 euros from the French…
Sanofi clarifies its ambitions for new vaccines, including messenger RNA
The headquarters of Sanofi, May 31, 2023 in Paris (AFP/Archives/ALAIN JOCARD) Sanofi wants to lead at least five innovative vaccines on the road to potential commercialization by 2025 and is…
Are we going to have a pancreatic cancer vaccine? Real hope thanks to messenger RNA
Yasmina Kattou / Photo credit: TEK IMAGE / ABO / SCIENCE PHOTO LIBRARY VIA AFP 07:17, May 12, 2023modified to 07:31, May 12, 2023 In the very serious scientific journal…
Covid: China approves its first messenger RNA vaccine
By Le Figaro with AFP Published on 03/22/2023 at 11:22 , Update on 03/22/2023 at 11:26 The vaccine was designed by the pharmaceutical group CSPC. Tobias Arhelger / stock.adobe.com China…
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE RNA LEADERS EUROPE CONGRESS IN BASEL – 03/13/2023 at 08:00
MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for administering active ingredients in nano micelles by the oral route, Aonys®, announces its participation in…
Influenza: mixed interim results for Moderna’s messenger RNA vaccine
By Le Figaro with AFP Published on 02/17/2023 at 06:17 , Update on 02/17/2023 at 08:01 This technology is the same as that used for its vaccine against Covid-19. The…
Moderna to open messenger RNA vaccine factory in Australia
The site will produce 100 million doses of vaccine per year, against Covid-19, influenza and other diseases. The Moderna laboratory announced on Monday the opening of a messenger RNA vaccine…
MEDESIS PHARMA receives a grant from AFM-TELETHON to finance the first phases of the development of NanosiRNA-HD, its RNA interference treatment for Huntington’s disease – 07/20/2022 at 08:00
Montpellier, July 20, 2022 at 8:00 a.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® technology for the administration of active ingredients in…
the United States authorizes the Novavax vaccine, which uses a more traditional technique than messenger RNA
The American Medicines Agency (Food and Drug Administration, FDA) authorized, on Wednesday July 13, the vaccine against Covid-19 from Novavax for adults 18 years of age and older. Produced by…